1.6B, trading at HK$58.10 on the HKSE. This SniperIQ fundamentals page covers Shanghai Henlius Biotech's valuation (P/E 33.0x, P/B 7.0x), profitability (net margin 12.4%), revenue (¥6.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
1.6B
P/E (TTM)33.0x
Net Margin12.4%
Revenue (FY25)¥6.7B

Full research coverage

Frequently Asked Questions

What is Shanghai Henlius Biotech's market cap?

Shanghai Henlius Biotech (2696) has a market capitalization of approximately HK

1.6B, trading at HK$58.10 on the HKSE. Market cap moves with the live share price.

What is Shanghai Henlius Biotech's P/E ratio?

Shanghai Henlius Biotech's trailing twelve-month P/E ratio is 33.0x, with a price-to-book (P/B) of 7.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Shanghai Henlius Biotech?

Shanghai Henlius Biotech runs a net profit margin of 12.4%, a gross margin of 74.7%, and an operating margin of 12.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Shanghai Henlius Biotech generate?

Shanghai Henlius Biotech reported revenue of ¥6.7B for fiscal year 2025, with net income of ¥806M and earnings per share (EPS) of 1.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Shanghai Henlius Biotech pay a dividend?

Shanghai Henlius Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Shanghai Henlius Biotech financially healthy?

Shanghai Henlius Biotech carries a debt-to-equity ratio of 0.91x and a current ratio of 0.71x, with a market beta of 0.50. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Shanghai Henlius Biotech a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai Henlius Biotech (2696) the key facts are: market cap HK

1.6B, P/E 33.0x, revenue ¥6.7B, 52-week range 53.05-92. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Shanghai Henlius Biotech's full fundamentals live

Get Shanghai Henlius Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.